Dylan Dupuis
Stock Analyst at Roth MKM
(2.78)
# 1,994
Out of 5,044 analysts
8
Total ratings
50%
Success rate
43.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dylan Dupuis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMMB Chemomab Therapeutics | Reinstates: Buy | $28 | $3.09 | +806.15% | 2 | Dec 19, 2023 | |
| IVA Inventiva | Reiterates: Buy | $11 | $4.16 | +164.42% | 2 | Sep 21, 2023 | |
| TERN Terns Pharmaceuticals | Reiterates: Buy | $23 | $8.02 | +186.78% | 3 | Aug 8, 2023 | |
| VKTX Viking Therapeutics | Assumes: Buy | $32 | $35.22 | -9.14% | 1 | May 31, 2023 |
Chemomab Therapeutics
Dec 19, 2023
Reinstates: Buy
Price Target: $28
Current: $3.09
Upside: +806.15%
Inventiva
Sep 21, 2023
Reiterates: Buy
Price Target: $11
Current: $4.16
Upside: +164.42%
Terns Pharmaceuticals
Aug 8, 2023
Reiterates: Buy
Price Target: $23
Current: $8.02
Upside: +186.78%
Viking Therapeutics
May 31, 2023
Assumes: Buy
Price Target: $32
Current: $35.22
Upside: -9.14%